Latest Articles
Endometriosis, fibroids and heavy periods: long-term research supports treatment decisions - NIHR Evidence
Endometriosis, fibroids and heavy periods: long-term research supports treatment decisions NIHR Evidence
Published: Dec. 4, 2024, 8 a.m.
Endometriosis: ‘It’s so frustrating and isolating to know there’s something wrong with your body but to not be believed’ - The Irish Times
Endometriosis: ‘It’s so frustrating and isolating to know there’s something wrong with your body but to not be believed’ The Irish Times
Published: Dec. 4, 2024, 6:02 a.m.
Endometriosis: ‘If I was believed 10 years ago, maybe it wouldn’t be this extensive’ - The Irish Times
Endometriosis: ‘If I was believed 10 years ago, maybe it wouldn’t be this extensive’ The Irish Times
Published: Dec. 4, 2024, 6:02 a.m.
What is Visanne, the endometriosis drug just added to the PBS? - New Zealand Doctor Online
What is Visanne, the endometriosis drug just added to the PBS? New Zealand Doctor Online
Published: Dec. 4, 2024, 1:33 a.m.
NMPA greenlights new endometrial cancer therapy - Investing.com India
NMPA greenlights new endometrial cancer therapy Investing.com India
Published: Dec. 4, 2024, 1:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News - StockTitan
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News StockTitan
Published: Dec. 4, 2024, 12:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News - StockTitan
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News StockTitan
Published: Dec. 4, 2024, midnight
Woman's Doctor: Know the symptoms of endometrial cancer - MSN
Woman's Doctor: Know the symptoms of endometrial cancer MSN
Published: Dec. 3, 2024, 8:37 p.m.
Elagolix with add-back therapy found effective and tolerable for endometriosis pain - Contemporary Obgyn
Elagolix with add-back therapy found effective and tolerable for endometriosis pain Contemporary Obgyn
Published: Dec. 3, 2024, 6:36 p.m.
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive
Published: Dec. 3, 2024, 5:11 p.m.
Link copied to clipboard!